TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01016912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Tablets, Oral, 10 mg, daily, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Tablets, Oral, 10 mg, daily, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Tablets, Oral, 60 mg, daily, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Tablets, Oral, 60 mg, daily, 24-48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, daily, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2b
Description: Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
Study: NCT00204711

Intervention type: OTHER
Intervention: SNAP II EEG System
Description: A portable EEG monitor (SNAP II EEG System, Everest -St. Louis) is unique in that it monitors both low frequency EEG signals (1-40 Hz), which are typically used, and high frequency EEG signals (80-420 Hz), which are not usually used, and calculates a derived EEG parameter (the SNAP Index). The SNAP Index ranges from 100 (completely awake) to 0 (no brain activity) and has been shown in a few studies to correlate with increasing sedation and loss of consciousness in human volunteers and patients receiving general anesthesia during surgery.
Study: NCT02173470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT scan
Description: The intervention group receives both standard care (chest x-ray) and an ultra low dose CT thorax without contrast.
Study: NCT03094468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-3058 (terbinafine hydrochloride 10%)
Description: Patients will apply the P-3058 nail solution once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of P-3058
Description: Patients will apply the Vehicle of P-3058 once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
Study: NCT03735056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MS Nurse Support
Description: MS Nurse Support intervention is multi-faceted, involving various components (i.e. information provision and emotional support), and a range of strategies and techniques (e.g. psychoeducation, acceptance and commitment), delivered by MS Nurse Specialists, to provide standardised support and advice to patients at diagnosis, to establish and sustain coping strategies. MS Nurse Support intervention is person-centred and tailored to the needs and lifestyle of each participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MS Nurse Support
Description: MS Nurse Support intervention is multi-faceted, involving various components (i.e. information provision and emotional support), and a range of strategies and techniques (e.g. psychoeducation, acceptance and commitment), delivered by MS Nurse Specialists, to provide standardised support and advice to patients at diagnosis, to establish and sustain coping strategies. MS Nurse Support intervention is person-centred and tailored to the needs and lifestyle of each participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: Peer Support will be delivered by Peer Support Workers using information provision and supportive listening to provide support and advice to patients at diagnosis, and to provide patients the opportunity to talk freely, extensively and confidentially about their experiences, thoughts and feelings about MS diagnosis and its effects on their lives in a non-judgmental and safe environment. Peer Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
Study: NCT00132665

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A: Radiotherapy alone
Description: Procedure/Surgery: A: Radiotherapy alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: CBDCA and Radiotherapy
Description: Drug: B: CBDCA and Radiotherapy
Study: NCT01274104

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 15,000 IU of Vitamin D3 every day for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03007680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core muscle activation
Study: NCT02919709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood taking
Study: NCT01778673

Intervention type: PROCEDURE
Intervention: Cast immobilization

Intervention type: PROCEDURE
Intervention: Cast immobilization
Study: NCT04271423

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ridge Preservation
Description: Ridge Preservation using demineralized bone matrix and mineralized particulate allograft and covered with calcium sulfate barrier.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge Preservation
Description: Ridge Preservation using demineralized bone matrix and mineralized particulate allograft and covered with calcium sulfate barrier.
Study: NCT05661006

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Use of food supplement
Description: On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute).~In the following days: continuation of consumption of test product once per day until end of the intervention. Subjects are recording daily consumption of the product. Intervention diet recording during last week of intervention (days 49-56): 3x24h dietary records (two days during weekday, one weekend day).~Intervention end on day 56 ±3 (fasted condition):~Measuring S-25-OH-VitD, S-VitB12, S-protein, S-albumin, S-CRP Measuring body weight \& height Collecting data regarding the palatability of the product

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Use of placebo food supplement
Description: On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end
Study: NCT03332225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Treatment with anakinra

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon-gamma
Description: Treatment with recombinant human interferon-gamma
Study: NCT03258827

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Home-based exercise
Description: Home-based program focuses on walking activity at fast speed, 3 times/week, 60 minutes/times. The total duration is 3 months.
Study: NCT01977586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Study: NCT01687894

Intervention type: DRUG
Intervention: sevoflurane
Description: vasopressins sevoflurane placebo sevoflurane

Intervention type: DRUG
Intervention: sevoflurane
Description: vasopressins sevoflurane placebo sevoflurane
Study: NCT00959634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: Dose administered twice daily on Study Days 1-10

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose administered twice daily on Study Days 1-10
Study: NCT04384757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal gastrectomy
Description: Distal gastrectomy and standard D2 lymphadenectomy
Study: NCT02107924

Intervention type: PROCEDURE
Intervention: APPI of TKR-Stimulan
Study: NCT03305250

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Loop Recorder
Description: An implantable loop recorder (ILR), also known as an insertable cardiac monitor, is a small device (smaller than a AAA battery) that is inserted under the skin on the front of the chest. The ILR is inserted using local anesthetic as an out-patient procedure and lasts approximately 30 minutes. The ILR captures a continuous ECG of your heart activity, which allows doctors to detect any abnormal heart rhythms at any point. If you have the ILR, you will have the device for 3 years, after which it will be removed under local anesthetic during an out-patient procedure, again lasting approximately 30 minutes. The ILR device is completely safe and shouldn't affect your day to day living.
Study: NCT04353635

Intervention type: DEVICE
Intervention: dolphin 3d
Description: software
Study: NCT04384757

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal gastrectomy
Description: Distal gastrectomy and standard D2 lymphadenectomy
Study: NCT05320991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine is applied with a Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA). Target plasma levels are 100 ng/ml with an initial bolus administered as a 2 mg/ml solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nacl 0.9%
Description: Saline solution will also be applied with the Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA).
Study: NCT03258034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPA
Description: S1/Paclitaxel chemotherapy plus Apatinib S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:425mg once daily
Study: NCT03643445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Orientated Treatment
Description: The motivation-oriented treatment condition is intended to create a context for treatment that is patient-centered, non-judgmental, and will create a therapeutic environment wherein patients can make an informed decision around their goals for treatment and their willingness to commit to the behavioural changes required for recovery from an eating disorder. In general, MI is a psychotherapeutic stance aimed at helping patients in resolving ambivalence toward change and increasing their intrinsic motivation to engage in healthy behaviour choices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation-Oriented Treatment
Description: The psychoeducation-oriented treatment condition is intended to teach patients about the causes of eating disorders, the expected course of recovery, obstacles to recovery, and the importance of behavioural changes required for recovery from an eating disorder. In this condition, in order to maximize the differences between groups, no attention will be given to discussing the patient's stage of change, their level of motivation, or their own personal values around recovery. Rather, emphasis during individual meetings with their therapist will be on the importance of symptom abstinence and normal eating.
Study: NCT03190070

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ingestion of protein
Description: Oral protein load as a physiological stimulus to temporarily increase glomerular filtration rate
Study: NCT02638142

Intervention type: DRUG
Intervention: Continuous Furosemide Infusion
Description: Intravenous continuous Furosemide infusion

Intervention type: DRUG
Intervention: Intermittent Furosemide Infusion
Description: Intravenous bolus intermittent Furosemide Infusion
Study: NCT01622855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPRS
Description: Video including psycho-education and modeling of adaptive behavioral coping strategies for use post-assault.
Study: NCT00080145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Study: NCT01443572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane anesthetics
Description: 40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane anesthetics
Description: 40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
Study: NCT02108496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NUsurface® Meniscus Implant
Description: The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
Study: NCT00080145

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavior Therapy
Study: NCT02108496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID's and Non-surgical Treatment Options
Description: Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-Articular Injections with Corticosteroids
Description: Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-Articular Injections with Hyaluronic Acid (HA)
Description: Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
Study: NCT02263859

Intervention type: DEVICE
Group type: OTHER
Intervention: aura6000 System
Description: The aura6000 System is intended to unilaterally stimulate the hypoglossal nerve which innervates the muscles of the tongue. The aura6000 System stimulates the hypoglossal nerve cyclically and continuously during sleep to maintain muscle tone of the tongue and upper airway during sleep. Stimulation is generated by a programmable, multi-current source, implantable neurostimulator (IPG) and delivered to the hypoglossal nerve by a lead with multi-contact cuff electrode (lead).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aura6000 System
Description: The aura6000 System is intended to unilaterally stimulate the hypoglossal nerve which innervates the muscles of the tongue. The aura6000 System stimulates the hypoglossal nerve cyclically and continuously during sleep to maintain muscle tone of the tongue and upper airway during sleep. Stimulation is generated by a programmable, multi-current source, implantable neurostimulator (IPG) and delivered to the hypoglossal nerve by a lead with multi-contact cuff electrode (lead).
Study: NCT06245902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and Acetaminophen
Description: Naltrexone plus acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and Acetaminophen-High Dose
Description: Naltrexon (high dose) plus acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Alone (regular dose)
Description: Naltrexone Alone plus Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen Alone
Description: Acetaminophen Alone plus Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Two Placebo capsules
Study: NCT02736175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Study: NCT02848586

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECIGS
Description: 15 subjects will receive ECIGs and 5 control subjects will continue to smoke their chosen usual brand of combustible cigarettes (UB). Each group will receive either ECIG or UB for a total of 4 weeks and undergo pulmonary and behavioral assessments during this period. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. Participants in the UB group will also undergo mCM procedures, but contingencies will differ. After 4 weeks, the ECIG group will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks with additional pulmonary and behavioral assessments. All subjects will undergo three respiratory assessments in the DCRU.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mobile contingency management (mCM)
Description: mCM procedures are a novel smoking cessation tool previously used in the field by our colleagues in the Beckham research group. This equipment is part of a procedure called mobile contingency management or mCM. The participant will use a study smartphone to record his/her CO levels and moods at random times of the day and to verify his/her cigarette usage. The mCM program will reward the participant for each CO level and data transmitted to the study team. The study team will provide detailed information and training to allow them to participate in this part of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mobile contingency management (mCM)
Description: mCM procedures are a novel smoking cessation tool previously used in the field by our colleagues in the Beckham research group. This equipment is part of a procedure called mobile contingency management or mCM. The participant will use a study smartphone to record his/her CO levels and moods at random times of the day and to verify his/her cigarette usage. The mCM program will reward the participant for each CO level and data transmitted to the study team. The study team will provide detailed information and training to allow them to participate in this part of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual brand
Description: The usual brand of cigarettes is the control group in this study. 5 participants will be allowed to continue using their usual brand of combustible cigarette in this arm of the study.
Study: NCT03700697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Stress Module Intervention
Description: as above
Study: NCT03856762

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: traditional Jiangnan diet
Description: traditional Jiangnan diet supplement from Monday to Friday for six months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Mediterranean diet supplement from Monday to Friday for six months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Current Shanghai diet
Description: current Shanghai diet supplement from Monday to Friday for six months
Study: NCT04484324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
Study: NCT02908971

Intervention type: BEHAVIORAL
Intervention: soy based formula at infancy
Description: The intervention is only past history of soy consumption
Study: NCT01750190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study: NCT00742209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1838262
Description: Flexible dosing: 1200 mg/day, 1800 mg/day, 2400 mg/day and 3000 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1838262
Description: Flexible dosing: 1200 mg/day, 1800 mg/day, 2400 mg/day and 3000 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1838262
Description: Flexible dosing: 1200 mg/day, 1800 mg/day, 2400 mg/day and 3000 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1838262
Description: Flexible dosing: 1200 mg/day, 1800 mg/day, 2400 mg/day and 3000 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-control
Study: NCT02493660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InSpace sub-acromial tissue spacer system
Description: Arthroscopic implantation of InSpace sub-acromial tissue spacer system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial repair of rotator cuff
Description: Arthroscopic partial repair of rotator cuff
Study: NCT02288312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Study: NCT02070640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of indocyanine green (ICG)
Description: 2.5 mg of of ICG will be injected intravenously 60-30 minutes prior to surgery in order to visualize the biliary tree using a near-infrared light source and camera. An additional 2.5 mg of IV ICG may be given intraoperatively if fluorescence has faded prior to visualization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Cholangiography Fluorescence (NIRF-C)
Description: These devices are used to identify anatomy, using infrared light that causes the ICG to fluoresce.
Study: NCT04249115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nano-Pulse Stimulation (NPS)
Description: Electrical pulses (nanosecond duration) applied directly to target SK lesions using sterile single-patient use treatment tips with microneedles.